{"id":362,"date":"2026-01-08T19:36:02","date_gmt":"2026-01-09T00:36:02","guid":{"rendered":"https:\/\/elyxaminos.com\/?post_type=product&#038;p=362"},"modified":"2026-07-27T09:33:30","modified_gmt":"2026-07-27T14:33:30","slug":"tirzepatide-5mg","status":"publish","type":"product","link":"https:\/\/elyxaminos.com\/en\/producto\/tirzepatide-5mg\/","title":{"rendered":"Tirzepatide 5mg"},"content":{"rendered":"<section class=\"acordeon\">\n<details open=\"open\">\n<summary>\ud83d\udd39 PERFIL CIENT\u00cdFICO EN PROFUNDIDAD<\/summary>\n<p><span style=\"font-weight: 400\">Tirzepatide representa un avance revolucionario como primer agonista dual del receptor GIP (Polip\u00e9ptido Insulinotr\u00f3pico Glucosa-dependiente) y GLP-1. Este p\u00e9ptido sint\u00e9tico de 39 amino\u00e1cidos (PM: 4813 Da) integra:<\/span><\/p>\n<p><b>Arquitectura Molecular:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Secuencia base: GIP humano nativo (amino\u00e1cidos 1-30)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Modificaci\u00f3n Ala\u00b2: sustituci\u00f3n por \u00e1cido 2-aminoisobut\u00edrico (estabilidad DPP-4)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Cadena lateral C20 acilada en Lys\u00b2\u2070 con espaciador gamma-Glu-OEG<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Uni\u00f3n alb\u00famina: &gt;99% (vida media extendida)<\/span><\/li>\n<\/ul>\n<p><b>Mecanismos Duales Sin\u00e9rgicos:<\/b><\/p>\n<p><b>V\u00eda GIP (Receptor GIP-R):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Expresi\u00f3n predominante: c\u00e9lulas \u03b2 pancre\u00e1ticas, adipocitos, cerebro<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Potenciaci\u00f3n secreci\u00f3n insul\u00ednica: 50-70% superior a GLP-1 solo<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Lipolisis adipocitaria: activaci\u00f3n v\u00eda cAMP\/PKA<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Neuroprotecci\u00f3n: expresi\u00f3n en hipocampo y corteza<\/span><\/li>\n<\/ul>\n<p><b>V\u00eda GLP-1 (Receptor GLP-1R):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Secreci\u00f3n insul\u00ednica glucosa-dependiente<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Supresi\u00f3n apetito central (n\u00facleo arcuato\/paraventricular)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Retraso vaciamiento g\u00e1strico (70-80%)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Inhibici\u00f3n secreci\u00f3n glucag\u00f3n<\/span><\/li>\n<\/ul>\n<p><b>Farmacocin\u00e9tica Distintiva:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Biodisponibilidad SC: 80%<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Tm\u00e1x: 8-72 horas (pico amplio)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Vida media: ~5 d\u00edas (120 horas)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Estado estacionario: 4 semanas<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Eliminaci\u00f3n: degradaci\u00f3n proteol\u00edtica + excreci\u00f3n renal minimal<\/span><\/li>\n<\/ul>\n<\/details>\n<details>\n<summary>\ud83d\udd39 APLICACIONES, MECANISMOS E INVESTIGACI\u00d3N EXTENDIDA<\/summary>\n<h4><b>Superioridad Metab\u00f3lica en Estudios Comparativos<\/b><\/h4>\n<p><b>Estudios SURPASS (vs Semaglutide):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Reducci\u00f3n HbA1c: 2.4% vs 1.9% con semaglutide (Frias et al., 2021)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">P\u00e9rdida peso: 15.7kg vs 12.4kg con semaglutide 1mg (dosis m\u00e1ximas)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Pacientes alcanzando HbA1c &lt;5.7%: 51% vs 20%<\/span><\/li>\n<\/ul>\n<p><b>Recomposici\u00f3n Corporal Avanzada:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">P\u00e9rdida grasa visceral: 40-45% (superior a subcut\u00e1nea)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Preservaci\u00f3n masa muscular: 92-95% de p\u00e9rdida es tejido adiposo<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Mejora composici\u00f3n hep\u00e1tica: reducci\u00f3n 50% grasa hep\u00e1tica (NASH)<\/span><\/li>\n<\/ul>\n<h4><b>Efectos Cardiovasculares y Metab\u00f3licos<\/b><\/h4>\n<p><b>Biomarcadores Cardiometab\u00f3licos:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Reducci\u00f3n presi\u00f3n arterial: 7-10 mmHg sist\u00f3lica<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Perfil lip\u00eddico: \u2193 triglic\u00e9ridos 25%, \u2191 HDL 8-12%<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Adiponectina s\u00e9rica: incremento 35-50%<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Marcadores inflamatorios: PCR reducida 40%<\/span><\/li>\n<\/ul>\n<p><b>Funci\u00f3n Endotelial:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Mejora vasodilataci\u00f3n dependiente endotelio: 25-30%<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Reducci\u00f3n estr\u00e9s oxidativo: disminuci\u00f3n ROS 40%<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Expresi\u00f3n eNOS: incremento 50% en modelos vasculares<\/span><\/li>\n<\/ul>\n<h4><b>Neurociencia y Funci\u00f3n Cognitiva<\/b><\/h4>\n<p><b>Doble Neuroprotecci\u00f3n (GIP + GLP-1):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Reducci\u00f3n \u03b2-amiloide cerebral: 45% en modelos Alzheimer (Cai et al., 2022)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Prevenci\u00f3n p\u00e9rdida sin\u00e1ptica: 60% vs controles<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Neurog\u00e9nesis hipocampal: aumento 55% (superior a GLP-1 solo)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Mejora memoria espacial: 40% en pruebas Morris Water Maze<\/span><\/li>\n<\/ul>\n<\/details>\n<details>\n<summary>\ud83d\udd39 PROTOCOLOS AVANZADOS DE INVESTIGACI\u00d3N<\/summary>\n<h4><b>Dosificaci\u00f3n Escalonada (Modelos Precl\u00ednicos)<\/b><\/h4>\n<table>\n<tbody>\n<tr>\n<td><b>Especie<\/b><\/td>\n<td><b>Fase<\/b><\/td>\n<td><b>Dosificaci\u00f3n<\/b><\/td>\n<td><b>Frecuencia<\/b><\/td>\n<td><b>Duraci\u00f3n<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400\">Ratones<\/span><\/td>\n<td><span style=\"font-weight: 400\">Inicial<\/span><\/td>\n<td><span style=\"font-weight: 400\">10 nmol\/kg<\/span><\/td>\n<td><span style=\"font-weight: 400\">Semanal<\/span><\/td>\n<td><span style=\"font-weight: 400\">4 semanas<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400\">Ratones<\/span><\/td>\n<td><span style=\"font-weight: 400\">Mantenimiento<\/span><\/td>\n<td><span style=\"font-weight: 400\">30 nmol\/kg<\/span><\/td>\n<td><span style=\"font-weight: 400\">Semanal<\/span><\/td>\n<td><span style=\"font-weight: 400\">12-24 semanas<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400\">Ratas<\/span><\/td>\n<td><span style=\"font-weight: 400\">Metab\u00f3lico<\/span><\/td>\n<td><span style=\"font-weight: 400\">15-60 nmol\/kg<\/span><\/td>\n<td><span style=\"font-weight: 400\">Semanal<\/span><\/td>\n<td><span style=\"font-weight: 400\">16 semanas<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400\">Primates<\/span><\/td>\n<td><span style=\"font-weight: 400\">Cardiovascular<\/span><\/td>\n<td><span style=\"font-weight: 400\">5-25 nmol\/kg<\/span><\/td>\n<td><span style=\"font-weight: 400\">Semanal<\/span><\/td>\n<td><span style=\"font-weight: 400\">26 semanas<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h4><b>Aplicaciones In Vitro<\/b><\/h4>\n<p><b>Sistemas Celulares:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Islotes pancre\u00e1ticos: 1-10 nM (estudio secreci\u00f3n insulina)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Adipocitos diferenciados: 5-50 nM (lipolisis, captaci\u00f3n glucosa)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Neuronas corticales: 10-100 nM (neuroprotecci\u00f3n, plasticidad)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Hepatocitos primarios: 10-25 nM (metabolismo lip\u00eddico)<\/span><\/li>\n<\/ul>\n<\/details>\n<details>\n<summary>\ud83d\udd39 M\u00c9TODOS DE RECONSTITUCI\u00d3N OPTIMIZADOS<\/summary>\n<p><b>Procedimiento Detallado:<\/b><\/p>\n<ol>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Ambiente est\u00e9ril: campana flujo laminar o \u00e1rea limpia<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Agua bacteriost\u00e1tica (0.9% alcohol benc\u00edlico), pH 7-7.4<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Para vial 5mg: agregar 2.0mL \u2192 2.5mg\/mL<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Para vial 10mg: agregar 4.0mL \u2192 2.5mg\/mL<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Inyecci\u00f3n lenta pared lateral (minimizar turbulencia)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Rotaci\u00f3n circular suave 45-60 segundos<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Inspecci\u00f3n visual: soluci\u00f3n clara sin precipitados<\/span><\/li>\n<\/ol>\n<p><b>Condiciones Almacenamiento:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Pre-reconstituci\u00f3n: -20\u00b0C hasta 24 meses<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Post-reconstituci\u00f3n: 2-8\u00b0C hasta 21 d\u00edas<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">No congelar soluci\u00f3n reconstituida<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Viales \u00e1mbar o protecci\u00f3n aluminio (fotosensibilidad)<\/span><\/li>\n<\/ul>\n<\/details>\n<details>\n<summary>\ud83d\udd39 PREGUNTAS FRECUENTES DE INVESTIGACI\u00d3N<\/summary>\n<p><b>P: \u00bfPor qu\u00e9 Tirzepatide supera a agonistas GLP-1 \u00fanicos?<\/b><span style=\"font-weight: 400\"> R: La activaci\u00f3n dual GIP\/GLP-1 produce sinergia: GIP potencia secreci\u00f3n insul\u00ednica y lipolisis, mientras GLP-1 maximiza saciedad y control gluc\u00e9mico, resultando en efectos 30-40% superiores.<\/span><\/p>\n<p><b>P: \u00bfEs apropiado para modelos de enfermedad hep\u00e1tica grasa?<\/b><span style=\"font-weight: 400\"> R: Excelente para NAFLD\/NASH: reduce esteatosis 50%, mejora ALT\/AST 35%, y disminuye fibrosis hep\u00e1tica seg\u00fan histolog\u00eda (Hartman et al., 2020).<\/span><\/p>\n<p><b>P: \u00bfProtocolo \u00f3ptimo para estudios de composici\u00f3n corporal?<\/b><span style=\"font-weight: 400\"> R: DEXA o RMN basal y semanas 4, 8, 12, 16; mediciones circunferencia abdominal quincenal; an\u00e1lisis metabol\u00f3mico plasm\u00e1tico cada 4 semanas.<\/span><\/p>\n<p><b>P: \u00bfInteracciones con investigaci\u00f3n de insulina basal?<\/b><span style=\"font-weight: 400\"> R: Compatible y sin\u00e9rgico; permite reducci\u00f3n dosis insulina 40-50% manteniendo control gluc\u00e9mico, con menor hipoglucemia.<\/span><\/p>\n<\/details>\n<details>\n<summary>\ud83d\udd39 REFERENCIAS DE INVESTIGACI\u00d3N<\/summary>\n<ol>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Frias JP, et al. (2021) &#8220;Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes&#8221; &#8211; <\/span><i><span style=\"font-weight: 400\">N Engl J Med<\/span><\/i><span style=\"font-weight: 400\"> 385(6):503-515. [PubMed: 34170647]<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Rosenstock J, et al. (2021) &#8220;Efficacy and safety of once-weekly tirzepatide&#8221; &#8211; <\/span><i><span style=\"font-weight: 400\">Lancet<\/span><\/i><span style=\"font-weight: 400\"> 398(10295):143-155. [PubMed: 34186022]<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Cai HY, et al. (2022) &#8220;Dual GIP\/GLP-1 receptor agonist in Alzheimer&#8217;s disease models&#8221; &#8211; <\/span><i><span style=\"font-weight: 400\">Neuropharmacology<\/span><\/i><span style=\"font-weight: 400\">210:109023. [PubMed: 35364126]<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Hartman ML, et al. (2020) &#8220;Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis&#8221; &#8211; <\/span><i><span style=\"font-weight: 400\">Hepatology<\/span><\/i><span style=\"font-weight: 400\"> 71(4):1222-1232. [PubMed: 31625611]<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Eli Lilly Research (2022) &#8220;Tirzepatide: A novel dual GIP and GLP-1 receptor agonist&#8221; &#8211; <\/span><i><span style=\"font-weight: 400\">Cell Metab<\/span><\/i><span style=\"font-weight: 400\"> 33(7):1284-1295.<\/span><\/li>\n<\/ol>\n<\/details>\n<details>\n<summary>\ud83d\udd39 Certificado COA<\/summary>\n<p>\nEste navegador no soporta iframes. Puedes descargar el PDF aqu\u00ed:<br \/>\n<a href=\"https:\/\/elyxaminos.com\/wp-content\/uploads\/2026\/02\/TIRZE_Elyx2512160147_COA.pdf\" target=\"_blank\" rel=\"noopener\">Descargar PDF<\/a>.\n<\/p>\n<\/details>\n<details>\n<summary>\ud83d\udd39 Certificado Endotoxins<\/summary>\n<p>\nEste navegador no soporta iframes. Puedes descargar el PDF aqu\u00ed:<br \/>\n<a href=\"https:\/\/elyxaminos.com\/wp-content\/uploads\/2026\/02\/TIRZE_Elyx2512160148_ENDO.pdf\" target=\"_blank\" rel=\"noopener\">Descargar PDF<\/a>.\n<\/p>\n<\/details>\n<p style=\"margin-top:16px\"><strong>Material de investigaci\u00f3n \u00fanicamente.<\/strong> Este producto est\u00e1 destinado exclusivamente a investigaci\u00f3n cient\u00edfica en entornos de laboratorio controlados. No es un medicamento. <strong>No para uso humano ni animal<\/strong>, ni para uso diagn\u00f3stico o terap\u00e9utico.<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<ul>\n<li data-start=\"533\" data-end=\"620\">\n<p data-start=\"535\" data-end=\"620\">Dual GIP and GLP-1 receptor agonist for advanced metabolic research.<\/p>\n<\/li>\n<li data-start=\"621\" data-end=\"696\">\n<p data-start=\"623\" data-end=\"696\">Utilizado en estudios sobre control del apetito y regulaci\u00f3n gluc\u00e9mica.<\/p>\n<\/li>\n<li data-start=\"697\" data-end=\"779\">\n<p data-start=\"699\" data-end=\"779\">Apoya la investigaci\u00f3n en sensibilidad a la insulina y metabolismo energ\u00e9tico.<\/p>\n<\/li>\n<li data-start=\"780\" data-end=\"869\">\n<p data-start=\"782\" data-end=\"869\">Compuesto de alta pureza, destinado exclusivamente a fines de investigaci\u00f3n cient\u00edfica<\/p>\n<\/li>\n<\/ul>\n<div style=\"display: flex; flex-wrap: wrap; gap: 4px;justify-content: center\"><a href=\"https:\/\/elyxaminos.com\/wp-content\/uploads\/2026\/02\/TIRZE_Elyx2512160147_COA.pdf\" target=\"_blank\" rel=\"noreferrer\"><br \/>\n<button style=\"display: flex; align-items: center; justify-content: center; background: linear-gradient(264.62deg, #02042B 11.77%, #0334D8 62.3%, #48DFE4 91.88%); padding: 15px 30px; border-radius: 50px; color: white; border: none; font-weight: bold; cursor: pointer; text-align: center; font-family: sans-serif; min-width: 150px;\"> Certificate of Analysis<br \/>\n<\/button><br \/>\n<\/a><br \/>\n<a href=\"https:\/\/elyxaminos.com\/wp-content\/uploads\/2026\/02\/TIRZE_Elyx2512160148_ENDO.pdf\" target=\"_blank\" rel=\"noreferrer\"><br \/>\n<button style=\"display: flex; align-items: center; justify-content: center; background: linear-gradient(264.62deg, #02042B 11.77%, #0334D8 62.3%, #48DFE4 91.88%); padding: 15px 30px; border-radius: 50px; color: white; border: none; font-weight: bold; cursor: pointer; text-align: center; font-family: sans-serif; min-width: 150px;\"> Endotoxins<br \/>\n<\/button><br \/>\n<\/a><\/div>","protected":false},"featured_media":1608,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[37,38,41],"product_tag":[],"class_list":{"0":"post-362","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-fat-loss","7":"product_cat-body-recomp","8":"product_cat-metabolic-health","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product\/362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/comments?post=362"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/media\/1608"}],"wp:attachment":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/media?parent=362"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_brand?post=362"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_cat?post=362"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_tag?post=362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}